Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03442088 · ClinicalTrials.gov registry record · Phase 2
Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast
A Phase 2 study, sponsored by University Hospitals Cleveland Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT03442088 is a Phase 2 study that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 28 participants.
The verdict
NCT03442088, a Phase 2 study, has completed, sponsored by University Hospitals Cleveland Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This is an open label pilot study of the impact of treatment with standard dosing of Otezla for 16 weeks on AM-endotype psoriasis patients, identified by elevated (\>150% of normal): 1.) Intermediate (CD14++CD16+) monocytes, or 2.) circulating monocyte doublets, or 3.) circulating monocyte-platelet aggregates (MPA). Approximately 25 psoriasis patients with the AM-endotype will be followed during treatment over 16 weeks with 4 monthly individual blood draws will be enrolled. All treated psoriasis subjects will receive apremilast through Week 16.
Interventions
- DRUG Apremilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2021-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03442088
The ClinicalTrials.gov registry entry for NCT03442088 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University Hospitals Cleveland Medical Center, which has 230 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Apremilast is the first listed.
NCT03442088 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03442088 about?
NCT03442088 is a clinical study titled "Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast". This is an open label pilot study of the impact of treatment with standard dosing of Otezla for 16 weeks on AM-endotype psoriasis patients, identified by elevated (\>150% of normal): 1.) Intermediate (CD14++CD16+) monocytes, or 2.) circulating monocyte doublets, or 3.) circulating monocyte-platelet ...
What is the current status of trial NCT03442088?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2018-06-01. Estimated completion is 2021-09-30.
What interventions are being tested in trial NCT03442088?
The interventions under investigation include: Apremilast (DRUG).
Who is sponsoring clinical trial NCT03442088?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.